DIRS.INFO The most relevant business & tech news

☆ Pfizer-BioNTech releases first human results on updated booster, citing an increase in antibodies
▼ + stars: | 2022-10-13 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com time to read: +3 min

The results are based on blood samples taken from adults one week after they received the updated booster. The FDA also authorized Moderna's updated booster based on similarly limited data. The FDA authorized the updated shots based on studies in mice — plus human trial results from a similar booster that targets the original omicron strain, called BA.1. At the time, Dr. Peter Marks, the FDA's top vaccine regulator, said the agency hoped the updated vaccines will provide stronger protection against symptomatic disease than the older vaccines. Moderna didn't immediately respond to a request for comment about when it will release new data on its updated booster.

Oct 13 (Reuters) - Pfizer (PFE.N) and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans. With the results, which the companies described as consistent with preclinical data, the partners are following up with human trial data that had previously been missing from their successful filings for regulatory approval. Register now for FREE unlimited access to Reuters.com RegisterThey did not disclose the levels of antibodies generated in the preliminary analysis of the study. Healthcare regulators for the European Union and the United States had already approved the upgraded shot last month, even though trial data from testing on humans had at the time not been available. “While we expect more mature immune response data from the clinical trial of our Omicron BA.4/BA.5-adapted bivalent vaccine in the coming weeks, we are pleased to see encouraging responses just one week after vaccination in younger and older adults," said Pfizer Chief Executive Albert Bourla.

☆ ‘Can You Believe I Lost to This Effing Guy?’ Trump Knew Biden Won, Aides Testify
▼ + stars: | 2022-10-13 | by ( ) www.wsj.com time to read: 1 min

Covid Vaccines Could Mirror the Flu Shot Process. Here’s What That MeansThe new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan Trefes

☆ Pfizer says omicron shots substantially boosted antibodies against BA.5 subvariant in early human data
▼ + stars: | 2022-10-13 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Pfizer and its German partner BioNTech on Thursday said their new omicron boosters substantially increased protective antibodies against the dominant omicron BA.5 subvariant for adults in the first direct human data released to the public on the new shots. The participants who received the first generation vaccine saw a limited increase in antibodies against BA.5, according to the companies. The early data indicate that the safety profile of the new boosters is the same as the original vaccine, the companies said. The first generation shots were developed only against the first strain of the virus. The FDA authorized the omicron shots without direct human data on how they perform against omicron BA.5, which is causing most infections in the U.S. right now.

☆ Repairs Under Way on Crimea Bridge as Trucks Wait for Days to Leave
▼ + stars: | 2022-10-13 | by ( ) www.wsj.com time to read: 1 min

☆ War Songs, Game Shows: The Propaganda That Helped Xi Cement Power
▼ + stars: | 2022-10-13 | by ( ) www.wsj.com time to read: 1 min

☆ Repairs Under Way on Crimea Bridge as Trucks Wait For Days to Leave
▼ + stars: | 2022-10-13 | by ( ) www.wsj.com time to read: 1 min

☆ U.S. authorizes updated COVID booster shots for children as young as 5
▼ + stars: | 2022-10-12 | by ( ) www.reuters.com time to read: +2 min

Oct 12 (Reuters) - U.S. health regulators authorized the use of Omicron-tailored COVID-19 booster shots from Moderna Inc (MRNA.O) and Pfizer Inc (PFE.N) in children as young as 5, a move that will expand the government's fall vaccination campaign. The U.S. Food and Drug Administration on Wednesday green-lighted Moderna's bivalent vaccine for those aged six and above, while Pfizer's updated shot was authorized in children aged five and above. The U.S. Centers for Disease Control and Prevention also backed the FDA's authorization, clearing the way for the shots to be administered in children. Overall, COVID-19 vaccination rates in the United States have stayed low among kids, with nearly 40% of children aged 5-11 vaccinated with one dose of a vaccine so far. Around 11.5 million people received the updated shots over the first five weeks of the rollout last month, which represents just 5.4% of the people aged 12 or older who are eligible to receive them.

☆ NASA’s DART Mission Declared a Success, Shifting Asteroid’s Orbit
▼ + stars: | 2022-10-11 | by ( ) www.wsj.com time to read: 1 min

Flu cases are already rising in parts of the U.S., according to the Centers for Disease Control and Prevention. The convergence of viruses is hitting health care systems as they're forced to reckon with staffing shortages that worsened during the pandemic. Staffing deficits mean there is little wiggle room to accommodate any additional surges of patients, whether they're sick with Covid, flu or other illness. But as the cold weather sets in and people increasingly gather indoors, Covid cases are expected to rise. The vast majority of Covid cases circulating now are an omicron subvariant, BA.5.

☆ Mortgages, Cars and Credit Cards: How Interest-Rate Hikes Are Hitting Americans' Wallets
▼ + stars: | 2022-10-10 | by ( Wall Street Journal | ) www.wsj.com time to read: 1 min

Covid Vaccines Could Mirror the Flu Shot Process. Here’s What That Means The new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan Trefes

☆ Swiss drugs regulator approves one of Pfizer's COVID-19 booster shots
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: 1 min

BERLIN, Oct 10 (Reuters) - Swiss drugs regulator Swissmedic said on Monday it had temporarily approved Pfizer's COVID-19 booster shot targeting the original and BA.1 Omicron coronavirus variants. Swissmedic added that the data currently available to it was not yet sufficient to make a decision on Pfizer's bivalent booster vaccine targeting the BA.4 and BA.5 Omicron variants. Register now for FREE unlimited access to Reuters.com RegisterWriting by Miranda Murray, editing by Rachel MoreOur Standards: The Thomson Reuters Trust Principles.

☆ Russia Hits Kyiv, Other Ukrainian Cities in Largest Missile Barrage in Months
▼ + stars: | 2022-10-10 | by ( ) www.wsj.com time to read: 1 min

☆ Watch: Eiffel Tower, Louvre Go Dark at Night Amid Europe Energy Crisis
▼ + stars: | 2022-10-09 | by ( ) www.wsj.com time to read: 1 min

☆ Thailand Families Mourn After Deadly Child-Care Center Shooting
▼ + stars: | 2022-10-07 | by ( ) www.wsj.com time to read: 1 min

☆ Watch: Rams’ Bobby Wagner Tackles Protester Running Onto Field
▼ + stars: | 2022-10-06 | by ( ) www.wsj.com time to read: 1 min

☆ Ford Races to Win Over Pickup Fans With F-150 Lightning
▼ + stars: | 2022-10-05 | by ( ) www.wsj.com time to read: 1 min

☆ Pfizer or Moderna: Which new omicron-specific Covid booster should you get?
▼ + stars: | 2022-09-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Americans have two options for a new omicron-specific Covid booster shot: Pfizer or Moderna. Pfizer's booster is cleared for anyone 12 and older, while Moderna's booster is for people 18 and older. "People ages 18 years and older may get a different product for a booster than they got for their primary series, as long as it is [Pfizer or Moderna,]" the CDC's website reads. "It's OK to mix and match Moderna and Pfizer," Dr. Ralph Gonzales, associate dean for clinical innovation at UC San Francisco, said at a campus town hall earlier this month. I definitely felt a stronger response with the Moderna — having had Pfizer before — but either combinations are fine."

☆ Pfizer wants approval for its Covid booster for children over 5 years old
▼ + stars: | 2022-09-26 | by ( The Associated Press | ) www.nbcnews.com time to read: +1 min

Pfizer asked U.S. regulators Monday to expand the use of its updated Covid-19 booster shot to children ages 5 to 11. Elementary school-aged children already received kid-sized doses of Pfizer’s original vaccine, a third of the dose given to everyone 12 and older — two primary shots plus a booster. Pfizer and its partner BioNTech also announced a new study of the omicron-focused booster in even younger children, those ages 6 months through 4 years, to test different doses. Updated boosters made by both Pfizer and rival Moderna rolled out earlier this month for everyone 12 and older. As of last week, the Centers for Disease Control and Prevention said 4.4 million Americans had gotten an updated booster so far.

☆ Pfizer, Moderna seek authorization for updated Covid-19 boosters for younger children
▼ + stars: | 2022-09-26 | by ( Naomi Thomas | ) edition.cnn.com time to read: +1 min

(CNN) Younger children could soon be eligible to receive an updated Covid-19 booster shot. Pfizer and BioNTech on Monday said they completed their submission to the US Food and Drug Administration for emergency use authorization of their updated Covid-19 booster for children ages 5 through 11. Moderna on Friday said it had requested FDA authorization for its updated booster for adolescents ages 12 to 17 and for children ages 6 to 11. Like the boosters that became available for older people earlier this month, these bivalent boosters target the original coronavirus strain as well as the Omicron BA.4/BA.5 subvariants. Pfizer's updated booster is currently authorized for use in people 12 and older and Moderna's is authorized for adults age 18 and older.

☆ Canada to remove all Covid travel restrictions from Oct. 1
▼ + stars: | 2022-09-26 | by ( ) www.cnbc.com time to read: +2 min

Cars line up at Canadian side of the border between Canada and the United States, near Seattle, Washington and Vancouver, British Columbia on August 9, 2021. Canada will drop all Covid-19 restrictions for travelers from Oct. 1, including vaccination and masking requirements for flights and trains, the government said on Monday. The move is likely to boost the Canadian travel industry, already booming after months of lull during the pandemic. More than 90% of Canadians over 12 have taken the primary series of a Covid vaccine. Cruise ship passengers and crew would also no longer be subject to vaccine requirements or Covid testing.

☆ Pfizer/BioNTech seek FDA nod for new COVID boosters for children
▼ + stars: | 2022-09-26 | by ( ) www.reuters.com time to read: +1 min

A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier/File PhotoSept 26 (Reuters) - Pfizer Inc (PFE.N) and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years. The rollout of bivalent booster doses for older age groups has been off to a slow start in the United States compared to the rollout of the first boosters last year, with 4.4 million doses administered so far. read moreEarlier in the month, the U.S. Centers for Disease Control and Prevention said it expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October. Register now for FREE unlimited access to Reuters.com RegisterReporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Savio D'SouzaOur Standards: The Thomson Reuters Trust Principles.

☆ Pfizer CEO tests positive for COVID for a second time
▼ + stars: | 2022-09-24 | by ( ) www.reuters.com time to read: +2 min

Register now for FREE unlimited access to Reuters.com RegisterAlbert Bourla, CEO of Pfizer attends a discussion at the World Economic Forum (WEF) in Davos, Switzerland May 25, 2022. REUTERS/Arnd WiegmannSept 24 (Reuters) - Pfizer Inc (PFE.N) Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19. Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech (22UAy.DE). A federal health agency said this week that over 25 million doses of the so-called bivalent shots had been sent out. read moreRegister now for FREE unlimited access to Reuters.com RegisterReporting by Mrinmay Dey in Bengaluru; Editing by Daniel WallisOur Standards: The Thomson Reuters Trust Principles.

☆ Less than 2% of U.S. adults have gotten updated Covid booster shots
▼ + stars: | 2022-09-23 | by ( Aria Bendix | Aria Bendix Is The Breaking Health Reporter For Nbc News Digital. | ) www.nbcnews.com time to read: +5 min

At least 4.4 million people have received an updated Covid booster since the start of the month, according to data released Thursday by the Centers for Disease Control and Prevention. The CDC signed off on updated versions of Pfizer’s and Moderna’s booster shots on Sept. 1, and pharmacies and other vaccination sites began administering the new shots around Labor Day weekend. As of Tuesday, the U.S. had shipped more than 25 million bivalent booster doses to tens of thousands of sites. Some pharmacies reported shortages of Moderna's updated booster earlier this week. Biden administration officials have pointed to the updated boosters, however, as a critical step to pushing the U.S. out of the pandemic.

☆ Moderna seeks FDA nod for Omicron-targeted COVID shot for adolescents, younger kids
▼ + stars: | 2022-09-23 | by ( ) www.reuters.com time to read: +1 min

Register now for FREE unlimited access to Reuters.com RegisterA vial labelled "Moderna COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The company is seeking emergency use authorization of its updated vaccine in two age groups - adolescents aged 12 to 17 years and children aged six to 11. Moderna's mRNA-1273.222, a bivalent booster shot, contains the dominant BA.4/BA.5 variants along with the original coronavirus strain. read moreThe U.S. government has ordered more than 170 million updated vaccine booster shots for this fall, and said on Tuesday it had sent out over 25 million doses to be distributed. Register now for FREE unlimited access to Reuters.com RegisterReporting by Mrinalika Roy in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "bivalent"

25 mentions found